Option chain shows key data for Imugene's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Imugene.

Imugene (OTC:IUGNF) Stock, Option Chain

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

Imugene Ltd

HC Wainwright &amp; Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Buy and maintains $55 price target.

News

Price Target

Reiteration

Analyst Ratings

TGTX

HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $55 Price Target

Investment giant&nbsp;BlackRock, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) stock is trading higher after the company&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42996688/blackrock-reports-full-year-2024-diluted-eps-of-42-01-or-43-61-as-adjusted-fourth-quarter-2024-dil" rel="noreferrer noopener">reported&nbsp;fourth-quarter&nbsp;results</a>.
Revenue grew 23% year over year to&nbsp;$5.68 billion, beating the consensus of&nbsp;$5.53 billion.&nbsp;
Investment advisory, administration fees, and securities lending revenues increased to&nbsp;$4.4 billion&nbsp;from&nbsp;$3.6 billion&nbsp;a year ago, led by higher organic base fee, the impact of market beta on average AUM and, around $230 million of fees related to AUM acquired in the GIP Transaction.
Technology services revenue rose to&nbsp;$428 million&nbsp;from&nbsp;$379 million&nbsp;the prior year, led by the successful onboarding of several new clients.
BlackRock stated that net inflow stood at&nbsp;$281 billion&nbsp;in the quarter and $641 billion in 2024.
Total AUM stood at&nbsp;$11.6 trillion at the end of the year compared to $10.0 trillion in 2023.
Adjusted operating income rose&nbsp;36%&nbsp;Y/Y to&nbsp;$2.33 billion, with the margin expanding to&nbsp;45.5%&nbsp;from&nbsp;41.6%&nbsp;a year ago.
Adjusted EPS increased&nbsp;23%&nbsp;Y/Y to&nbsp;$11.93,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$11.21.</a>
BlackRock repurchased shares worth&nbsp;$1.6 billion in the year.&nbsp;
Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42984073/banks-kick-off-earnings-season-on-wednesday-retail-traders-bet-big-on-financials-ahead-of-regulatory-tailwinds" rel="noreferrer noopener">Banks Kick Off Earnings Season On Wednesday: Retail Traders Bet Big On Financials Ahead Of Regulatory Tailwinds</a>
Laurence D. Fink, Chairman and CEO, said,&nbsp;&#8220;Client activity accelerated into the fourth quarter, resulting in 7% organic base fee growth and 12% technology services ACV growth.&#8221;
In December 2024, the company disclosed a definitive agreement to acquire&nbsp;HPS Investment&nbsp;Partners&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42296768/blackrock-makes-12-billion-power-move-acquires-hps-to-bolster-private-credit-offerings" rel="noreferrer noopener">for around $12 billion</a>.
This transaction strengthens BlackRock&#8217;s offerings for insurance clients. The deal is expected to increase private markets fee-paying AUM and management fees by 40% and 35%, respectively, and be modestly accretive to BlackRock&#8217;s as-adjusted earnings&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">per share in the first full year post-close</a>.
Fink added, &#8220;Our record organic growth and financial results do not yet reflect the full integration or pending acquisitions of the high-growth businesses of GIP, HPS and Preqin. And we&#8217;ve steadily made organic investments ahead of structural trends that we expect to drive outsized growth in the years ahead.&#8221;
Investors can gain exposure to the stock via&nbsp;Fidelity Disruptive Finance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDFF#NASDAQ">FDFF</a>) and&nbsp;Schwab US Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>).
Price Action: BLK shares are up 2.38% at $986.12 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42910264/trump-fallout-blackrock-exits-climate-alliance-cites-regulatory-pressure-and-client-confusion" target="_blank" rel="noreferrer noopener">Trump Fallout? BlackRock Exits Climate Alliance, Cites Regulatory Pressure And Client Confusion</a></li>
</ul>
Photo by rafapress on Shutterstock.

Earnings

Equities

Large Cap

Movers

FDFF

SCHD

BlackRock Q4 Earnings: Record Inflows Fuel Revenue And Earnings Beat, AUM Hits $11.6 Trillion Milestone

As part of the company's 2024 investment of more than $10 million to expand manufacturing capacity, new needle and syringe production lines have been installed at the BD plants in Connecticut and Nebraska. One line is already fully operational with additional lines expected to start up in the coming months.
These new lines will boost BD's capacity of domestically manufactured safety-engineered injection devices by more than 40 percent and conventional syringes by more than 50 percent, adding hundreds of millions of units annually to support critical U.S. health care delivery such as hospital procedures, vaccinations, medication preparation and drug delivery to patients. In addition, BD has hired more than 215 full-time employees at its facilities in Nebraska and Connecticut to support the increased production.

Becton, Dickinson And Company Says It Boosts US Manufacturing Of Critical Medical Devices: Among Others Company Plans Over $30M In Investments In 2025 To Expand Manufacturing Capacity For IV Lines At Its Plant In Utah   To Support Continued Growth In Catheter Solutions

WIIM

JPMorgan Chase shares are trading higher after the company reported better-than-expected Q4 EPS and revenues.

Janney Montgomery Scott analyst Robert Stevenson downgrades Douglas Emmett (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEI#NYSE">DEI</a>) from Buy to Neutral.

Downgrades

Janney Montgomery Scott Downgrades Douglas Emmett to Neutral

HC Wainwright &amp; Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and maintains $7 price target.

KPTI

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target

Wells Fargo Q4 Net Interest Income Decreased 7% YoY

DA Davidson analyst Michael Shlisky upgrades Shyft Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHYF#NASDAQ">SHYF</a>) from Neutral to Buy and maintains the price target from $15 to $15.

Upgrades

SHYF

DA Davidson Upgrades Shyft Group to Buy, Maintains Price Target to $15

MNSO

MINISO Says It Launched Flagship Store In Thailand, Building Another Landmark In SE Asia

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Integra Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#AMEX">ITRG</a>) with a Buy and lowers the price target from $3.75 to $2.

ITRG

HC Wainwright & Co. Maintains Buy on Integra Resources, Lowers Price Target to $2

As the weekend approaches, TikTok is on the verge of being banned in the United States unless the Supreme Court steps in to halt the process. 
What Happened: The potential ban of TikTok on Sunday could impact the app&#8217;s nearly 17,000 employees in the U.S., sparking a wave of uncertainty.
In the latter half of 2024, TikTok saw a 38% rise in employee departures compared to the same period in 2023, as per <a href="https://www.adweek.com/media/tiktoks-us-hiring-slowed/">Adweek</a>. Many former employees have transitioned to major tech companies such as Meta, Google, Amazon, Microsoft, and Apple.
Despite the increase in departures, TikTok&#8217;s hiring has&nbsp;slowed to its lowest level&nbsp;since 2020, with over 2,000 job openings still listed on its career site across various U.S. cities, covering roles in&nbsp;product, design, operations, advertising, and&nbsp;sales.
TikTok reportedly reassured its U.S. employees that their &#8220;employment, pay, and benefits are secure, and our offices will remain open, even if this situation hasn&#8217;t been resolved before the January 19 deadline,&#8221; Business Insider <a href="https://www.businessinsider.com/tiktok-tells-staff-still-have-jobs-if-ban-happens-memo-2025-1">reported</a> on Wednesday. 
The memo also noted that only the U.S. user experience would be impacted.
As TikTok awaits the Supreme Court&#8217;s decision, the company is preparing for various outcomes. Legal analysts suggest that the court is unlikely to overturn the existing ruling. Meanwhile, President-elect Donald Trump has expressed intentions to save the app once in office.
Why It Matters: The potential TikTok ban in the U.S. has been a topic of significant discussion, with the&nbsp;<a href="https://www.benzinga.com/general/social-media/25/01/42957741/tiktok-ban-deadline-ahead-what-will-happen-to-app-on-your-phone">Supreme Court</a>&nbsp;signaling support for enforcing the<a href="https://www.benzinga.com/general/social-media/25/01/42957741/tiktok-ban-deadline-ahead-what-will-happen-to-app-on-your-phone"> Jan. 19 deadline</a>. This has led to various speculations about what might happen to the app on users&#8217; phones and which companies could benefit from the ban.
In a surprising development,&nbsp;Elon Musk&nbsp;has emerged as a potential buyer for <a href="https://www.benzinga.com/general/social-media/25/01/42965533/elon-musk-emerges-as-potential-tiktok-us-buyer-as-ban-deadline-looms-company-terms-it-pure-fiction">TikTok&#8217;s U.S. operations</a>. Discussions, though preliminary, suggest a potential scenario where Musk's X platform could acquire TikTok's U.S. operations, valued between $40 billion to $50 billion. This move would merge TikTok's 170 million U.S. users with X's advertising reach.
Additionally,&nbsp;YouTuber MrBeast has also <a href="https://www.benzinga.com/general/social-media/25/01/42994923/mrbeast-discussing-buying-tiktok-with-billionaires-to-prevent-us-shutdown-lets-see-if-we-can-pull-this-off">expressed interest in acquiring TikTok </a>to prevent its shutdown. He is reportedly in talks with several billionaires to explore the feasibility of this purchase, although no names have been disclosed yet.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42988409/bitcoin-ethereum-xrp-dogecoin-move-higher-ahead-of-inflation-data-wednesday">Bitcoin, Ethereum, XRP, Dogecoin Move Higher Ahead Of Inflation Data Wednesday</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Social Media

General

TikTok Is Set To Be Banned In The US This Sunday Unless The Supreme Court Steps In: Here's What Happens To Its Nearly 17,000 American Workforce

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) reported quarterly earnings of $4.81 per share which beat the analyst consensus estimate of $4.11 by 17.03 percent. The company reported quarterly sales of $43.738 billion which beat the analyst consensus estimate of $41.707 billion by 4.87 percent. This is a 9.50 percent increase over sales of $39.943 billion the same period last year.

Earnings Beats

JPMorgan Chase Q4 2024 GAAP EPS $4.81 Beats $4.11 Estimate, Sales $43.738B Beat $41.707B Estimate

Wells Fargo shares are trading higher following a Q4 EPS beat.

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">IAC Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>)</h3>
<ul>
<li>After the market close on Monday, IAC announced its board approved a plan to spin off its full stake in Angi to IAC shareholders. As part of the change, IAC CEO Joey Levin will leave his role and become an advisor to the company. Levin will also be named executive chairman of Angi. "Joey Levin has wanted a store of his own for some time and the spin-off of Angi affords him this opportunity. Although IAC will relinquish his services as CEO, we expect that he will continue to advise us for many years," said Barry Diller, senior executive and chairman of IAC. The company' stock fell around 7% over the past month and has a <a href="https://www.benzinga.com/quote/IAC">52-week low of $39.61</a>.</li>
<li>RSI Value: 28.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>IAC Price Action: Shares of IAC gained 0.4% to close at $41.65 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">latest IAC news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="857" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064428/image-92.png" alt="" class="wp-image-734460" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064428/image-92.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064428/image-92-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064428/image-92-768x723.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">Fubotv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>)</h3>
<ul>
<li>On Jan. 6, FuboTV, along with The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), finalized a definitive agreement to combine Disney's Hulu + Live TV with Fubo, forming a combined virtual MVPD company. The company's stock fell around 29% over the past five days and <a href="https://www.benzinga.com/quote/FUBO">has a 52-week low</a> of $1.10.</li>
<li>RSI Value: 19.2</li>
<li>FUBO Price Action: Shares of Fubotv fell 14.4% to close at $3.81 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">FUBO stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="927" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064524/image-93.png" alt="" class="wp-image-734461" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064524/image-93.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064524/image-93-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064524/image-93-768x706.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
<h3 class="wp-block-heading">Getty Images Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>)</h3>
<ul>
<li>On Jan. 7, Getty Images and Shutterstock announced a $3.7 billion merger. The company's stock fell around 30% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/GETY">low of $2.06.</a></li>
<li>RSI Value: 24</li>
<li>GETY Price Action: Shares of Getty Images gained 5.7% to close at $2.58 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">GETY shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="892" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064619/image-94.png" alt="" class="wp-image-734462" style="width:548px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064619/image-94.png 892w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064619/image-94-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064619/image-94-768x730.png 768w" sizes="(max-width: 892px) 100vw, 892px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/42992639/how-to-earn-500-a-month-from-state-street-stock-ahead-of-q4-earnings">How To Earn $500 A Month From State Street Stock Ahead Of Q4 Earnings</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

FUBO

GETY

Top 3 Tech And Telecom Stocks That May Explode This Quarter

Wedbush analyst Nick Setyan reiterates Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Neutral and maintains $130 price target.

SHAK

Wedbush Reiterates Neutral on Shake Shack, Maintains $130 Price Target

Avino Silver & Gold Mines Reports That Underground Development At Its 100%-owned La Preciosa Property Has Commenced Following Receipt Of All Required Permits For Mining Operations

Earnings Misses

Macro Notification

Wells Fargo Q4 2024 GAAP EPS $1.43 Beats $1.34 Estimate, Sales $20.378B Miss $20.585B Estimate

Weyerhaeuser shares are trading higher after CIBC upgraded the stock from Neutral to Outperformer.

BlackRock shares are trading higher after the company reported better-than-expected Q4 financial results.

Wedbush analyst Nick Setyan reiterates Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Outperform and maintains $60 price target.

PZZA

Wedbush Reiterates Outperform on Papa John's International, Maintains $60 Price Target

Imugene Limited (AU:IMU) has released an update. Imugene Limited announced the successful passing of all resolutions at its Annual General Meeting,...

Imugene Limited Advances Amidst AGM Vote Challenges

Imugene Limited (AU:IMU) has released an update. Imugene Limited, a clinical-stage immuno-oncology company, has announced the resignation of Jens E...

Imugene Announces Board Changes Amid Cancer Therapy Focus

Imugene Limited (AU:IMU) has released an update. Imugene Limited announced that Jens Eckstein has ceased to be a director as of November 14, 2024, ...

Imugene Limited Announces Director Change and Stock Holdings

Imugene Limited (AU:IMU) has released an update. Imugene Limited, a clinical stage immuno-oncology company, has updated its Appendix 3Z document fo...

Imugene Limited Updates and Focus on Cancer Therapies

Imugene Limited (AU:IMU) has released an update. Imugene Limited has secured confirmation of an $11 million R&D tax refund from the Australian Taxa...

Imugene Limited Secures $11 Million R&D Tax Refund

Imugene Limited (AU:IMU) has released an update. Imugene Limited has announced that its allogeneic CAR T-cell therapy, azer-cel, will be showcased ...

Imugene's Azer-cel to be Featured at Major Conference

Imugene Limited (AU:IMU) has released an update. Imugene Limited has secured a significant capital boost of up to A$46 million through the issuance...

Imugene Secures A$46 Million for Clinical Trials

Imugene Limited (AU:IMU) has released an update. Imugene Limited has announced the dosing of the first Australian patient in its Phase 1b trial of ...

Imugene's Australian Trial for Innovative Cancer Therapy Begins

Imugene Limited ( ($AU:IMU) ) has provided an update. Imugene Limited has received an R&D tax refund of A$11.7 million for the 2023 financial year,...

Imugene Secures $11.7m R&D Tax Refund to Boost Cancer Therapy Development

Imugene Limited ( ($AU:IMU) ) has issued an update. Imugene Limited has announced the quotation of new securities on the Australian Securities Exch...

Comments

Imugene

Imugene (IUGNF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga